Beate Ludwig, PT | |
3801 Lake Otis Pkwy, Suite 300, Anchorage, AK 99508-5234 | |
(907) 562-2277 | |
(907) 563-3460 |
Full Name | Beate Ludwig |
---|---|
Gender | Female |
Speciality | Physical Therapy |
Experience | 34 Years |
Location | 3801 Lake Otis Pkwy, Anchorage, Alaska |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1598186884 | NPI | - | NPPES |
1648151 | Medicaid | AK |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2251X0800X | Physical Therapist - Orthopedic | PHYP2680 (Alaska) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Orthoalaska Llc | 2961705520 | 125 |
News Archive
UCLA scientists have shown that temporarily blocking a protein critical to immune response actually helps the body clear itself of chronic infection. Published in the April 12 edition of Science, the finding suggests new approaches to treating persistent viral infections like HIV and hepatitis C.
Some of America's most popular fish salmon and albacore tuna, for example are rich in healthful natural compounds known as omega-3 fatty acids. Ongoing studies by U.S. Department of Agriculture (USDA) chemist Darshan S. Kelley and co-investigators are helping uncover new details about how these fish-oil components help protect us from chronic diseases.
Offering patients the choice between home screening or in-office colonoscopy does not increase participation in colorectal cancer screening, according to a new Penn Medicine study.
Agilent Technologies Inc. today announced a solution for exon analysis based on SurePrint G3 Exon Microarrays. The solution provides a major expansion of Agilent's portfolio of gene expression reagents, microarrays and bioinformatics systems. This new system, available in mid-November, enables researchers to examine alternately expressed exons according to recently updated content, providing a global picture of RNA expression.
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
› Verified 7 days ago
Provider Name | Orthoalaska Llc |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1336504521 PECOS PAC ID: 2961705520 Enrollment ID: O20160114002729 |
News Archive
UCLA scientists have shown that temporarily blocking a protein critical to immune response actually helps the body clear itself of chronic infection. Published in the April 12 edition of Science, the finding suggests new approaches to treating persistent viral infections like HIV and hepatitis C.
Some of America's most popular fish salmon and albacore tuna, for example are rich in healthful natural compounds known as omega-3 fatty acids. Ongoing studies by U.S. Department of Agriculture (USDA) chemist Darshan S. Kelley and co-investigators are helping uncover new details about how these fish-oil components help protect us from chronic diseases.
Offering patients the choice between home screening or in-office colonoscopy does not increase participation in colorectal cancer screening, according to a new Penn Medicine study.
Agilent Technologies Inc. today announced a solution for exon analysis based on SurePrint G3 Exon Microarrays. The solution provides a major expansion of Agilent's portfolio of gene expression reagents, microarrays and bioinformatics systems. This new system, available in mid-November, enables researchers to examine alternately expressed exons according to recently updated content, providing a global picture of RNA expression.
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Beate Ludwig, PT 3801 Lake Otis Pkwy, Suite 300, Anchorage, AK 99508-5234 Ph: (907) 562-2277 | Beate Ludwig, PT 3801 Lake Otis Pkwy, Suite 300, Anchorage, AK 99508-5234 Ph: (907) 562-2277 |
News Archive
UCLA scientists have shown that temporarily blocking a protein critical to immune response actually helps the body clear itself of chronic infection. Published in the April 12 edition of Science, the finding suggests new approaches to treating persistent viral infections like HIV and hepatitis C.
Some of America's most popular fish salmon and albacore tuna, for example are rich in healthful natural compounds known as omega-3 fatty acids. Ongoing studies by U.S. Department of Agriculture (USDA) chemist Darshan S. Kelley and co-investigators are helping uncover new details about how these fish-oil components help protect us from chronic diseases.
Offering patients the choice between home screening or in-office colonoscopy does not increase participation in colorectal cancer screening, according to a new Penn Medicine study.
Agilent Technologies Inc. today announced a solution for exon analysis based on SurePrint G3 Exon Microarrays. The solution provides a major expansion of Agilent's portfolio of gene expression reagents, microarrays and bioinformatics systems. This new system, available in mid-November, enables researchers to examine alternately expressed exons according to recently updated content, providing a global picture of RNA expression.
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
› Verified 7 days ago
Katrina F Johnson, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-563-2662 | |
Jessie Lief, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4031 Winchester Loop, Anchorage, AK 99507 Phone: 907-244-8048 | |
Zoe Anneliese Morris Nelson, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1917 Abbott Rd Ste 200, Anchorage, AK 99507 Phone: 907-279-4266 | |
Normajean Farr, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 2221 E Northern Lights Blvd, Suite 106, Anchorage, AK 99508 Phone: 907-677-5605 | |
Mary Beth Nearing, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 602 W 42nd Ave, Anchorage, AK 99503 Phone: 907-360-9448 Fax: 907-346-1470 | |
Kids Are People Too Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6311 Debarr Rd, Suite J, Anchorage, AK 99504 Phone: 907-830-3592 Fax: 907-338-4691 | |
Ms. Catherine A Coward, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 9500 Independence Dr, Ste 900, Anchorage, AK 99507 Phone: 907-522-1341 Fax: 907-522-1343 |